Skip to content
NeuroTechGuide

Cadence Neuroscience gets FDA approval for biomarker-guided epilepsy stimulation study

The BTSEE study will test cortical stimulation guided by each patient's own brain signals in 45 children and adults with drug-resistant focal epilepsy.

Cadence Neuroscience, based in Redmond, Washington, said on October 14 that the FDA approved an Investigational Device Exemption for its BTSEE study. The study will test the company’s Biomarker Targeted Stimulation system, which uses each patient’s own neural biomarkers to guide stimulation and measures how the brain responds in real time. It will enroll 45 children and adults with drug-resistant focal epilepsy at up to 10 US epilepsy centers. Mayo Clinic epileptologist Gregory Worrell is the lead investigator. The results are meant to support a future Humanitarian Device Exemption application.

The approach grew out of Mayo Clinic research. A 2019 retrospective study of 21 patients given continuous low-level cortical stimulation reported promising seizure control, but this is the first prospective multicenter test. The system is investigational.

Learn more: Closed-loop system · ECoG

Share:XLinkedInBlueskyEmail

More news